Member Info for Retireby40

Gerry said in his presentation they had several contracts and early and late stage negotiations so I wouldn’t be surprised to get a few similar RNSs over the coming weeks. The total addressable marker is massive and we’ll see more CBD trials too. Still massively undervalued given the potential and what Gerry and the team are already going. Look at the turn around in some 10 months.

Increasing revenues from existing clients is the cheapest and most effective way to grow a business and if needs to go hand in hand with winning new business. I’m really impressed with the increase in revenues from ongoing ops and with the reduction in losses (in only 4 months they reduced the loss by 12%) due to divesting poor performing elements it looks healthy. Cash in the bank too and sales growing impressively into 19 and hopefully H2 will see revenues generated from the skin cloning product.

- FY 2018 revenue from continued operations GBP274k increased 294% (FY 2017 : GBP93k) following Labskin test kit sales move to full skin-care product test services;

-- FY 2018 EBITDA losses reduced by 12% to (GBP1.25m) (FY 2017: (GBP1.40m)) cost savings achieved under new management in the last 4 months of 2018;

And the price goes down. Big sell to be mopped up?

Given the loss was reduced to ?1.25m and with sales growing and underperforming assets divested the cash on the balance sheet should be sufficient to see us through this growth phase. I imagine money will only be raised for acquisitions. Exciting times.

I’ll buy some more once the fib retrace is complete so I expect we have further to fall (and Milton have the final lot to clear) before a substantial bounce and then steady climb. A not detailing am saying it how I see it. I’m a holder and am long BTW, just expecting to get some more lower.

When someone questioned where the contract RNSs are GB replied -

Can we get this straight? RNS updates have been detailed in broker notes and videos.
NDA's preclude us from identifying all major contracts. However there are companies who are clients who don't have as much restrictions. They are already in the public domain. They are even listed on the video of the Investor Event I gave last Monday.
How else would we be able to show sales more than doubling in H2 over H1 2018. How else are we able to show that is accelerating into 2019?
If you want to go further, as we have removed non-performing assets and reduced debt and overhead, it's more than obvious that operating costs in H2 2018 will be lower.
Adding RinoCloud since the beginning of the year revenues has increased because. This is already in the last RNS

Good work, i’ll repost on advfn.

Today 14:17Yu Group raised £11.6m in March '18 and ended the year with £9.7m more cash than Dec '17. As such they burnt £1.9m of the new placing money.
They look on track to make £88m to £100m revenue in '19 on a single digit margin north of 7.3%
Conservatively let's use 7.3% on £95m. That's £7m gross margin
Current marcap is £41m
7/41 = 17% gross margin to marcap at 252p

The Big Six energy suppliers profit margins hit an all-time high! ... Ofgem revealed that the average pre-tax profit margin amongst the big six energy suppliers increased from 4.15% to 4.48% in 2016

So does that make Yu Group a potential 2-4 bagger from here?
https://robinhoodenergy.co.uk/news/big-six-energy-suppliers-profit-margins/

Am surprised this isn’t above £3 but now a big sell has been worked I can see this motoring.

3 on the bid and 1 on the ask. Encouraging.

https://www.share-talk.com/integumen-plc-lonskin-ceo-gerry-brandon-move-into-clinical-trials/?utm_source=twitter&utm_medium=&utm_campaign=

The CEO said they’re getting lots incoming emails from interested parties and given they launched a new product on Friday they’re already in early and advanced negotiations. Bearing in mind there are thousands of products on our shelves and those around the EU that need to be tested before May 2020 to remain on those shelves the shirt term potential here is massive and #SKIN is already working with many of them so an easier sell. Also all new products coming to market need to do the same, #INTEGUMEN is so well placed to exploit this opportunity. Really massive potential with a CEO who has done it before and is driven and will no doubt do it again. A snip at current price.

From under the radar on advfn -

Now it’s a bull flag on the 6 month chart. That’s the first time since April and its more important than when it’s on the daily.

Why?

Because the longer timeframe charts hold more weight.We are on big wave 3 which is the strongest and the next flagpole will be really tall which means we will smash through the old high of 2.5p.

Couple this in with all the news that’s due and I see a short term target of 4.6p being reached.

This is the reason why I’m more than comfortable to sit on my hands and do absolutely nothing.

I was there too and have to say I couldn’t feel more comfortable with my holding which is pretty chunky. Wish I had mor cash to buy more. If I did I’d post positive comments after my purchases!

Looking forward to this evening too. CBD update soon, last RNS was on 25 March and then a month before so one could be imminent?! So many positive RNSs of late I’m getting greedy!

Gerry tweets back -

Relax, news to follow. You will need CBD to relax a bit and let #SKIN do its thing.

Agreed and let’s face it SLIN has a compelling story and a compelling CEO so I can only see new money being invested on Tuesday. I imagine existing holders don’t need persuading and most would have topped up already. New investors may also sell the story to others. Tomorrow should be interesting.

Share prices rarely go up in a straight line so a bit of selling and dips make a liquid market. This is looking strong and given there are a few CEOs presenting later I imagine many in the audience won’t know SKIN but i’d Expect our CEO to win them over given the potential here and I can only see new money pouring in tomorrow.

So the PR is impressive and the news released on Friday afternoon so some may have missed the boat on Friday. I expect some decent buying Monday morning but even more buying on Tuesday. The presentation is on Monday and there will be existing shareholders as well as others there to watch other CEOs who are presenting so I expect plenty of top ups and new money flooding in on Tuesday. I’d be surprised if we don’t surpass our 52 week high of 2.62p come the end of the week. Exciting times.

Yep existing products and ones coming to market.

Now there are hundreds, if not thousands, of products that need a quick solution to allow their products to stay on the shelves and that requires a fast-track approach I expect Labskin will be announcing a disruptive solution to address this in the Clinical research space shortly. Check!

And we’re re not past midday. Can really see 2p being secured. Gutted for those who sold out yesterday. Still time to buy back in as I’m sure the CEO will release a positive RNS on Monday, all the indications in blogs, podcasts and tweets suggest so.